Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polyps 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 118Peripheral Blood Stem Cell Transplantation 67Filgrastim 60Etoposide 60Rituximab 54fludarabine phosphate 50Vincristine 46Radiotherapy 46Methotrexate 46Cytarabine 44Doxorubicin 40Cyclosporine 35Mycophenolic Acid 33Busulfan 33Prednisone 32Whole-Body Irradiation 31Tacrolimus 28Antilymphocyte Serum 28Melphalan 27Dexamethasone 26Methylprednisolone 22Leucovorin 19Carmustine 18Granulocyte Colony-Stimulating Factor 17Calcium Dobesilate 16Ifosfamide 15Psychiatric Rehabilitation 13Cord Blood Stem Cell Transplantation 13sargramostim 12merphos 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Burkitt Lymphoma × Sennosides × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡